BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 9973516)

  • 1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.
    Delgado M; Pozo D; Martinez C; Leceta J; Calvo JR; Ganea D; Gomariz RP
    J Immunol; 1999 Feb; 162(4):2358-67. PubMed ID: 9973516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6.
    Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP
    J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages.
    Martínez C; Delgado M; Pozo D; Leceta J; Calvo JR; Ganea D; Gomariz RP
    J Leukoc Biol; 1998 May; 63(5):591-601. PubMed ID: 9581803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M; Ganea D
    J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
    Delgado M; Sun W; Leceta J; Ganea D
    J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
    Martinez C; Delgado M; Gomariz RP; Ganea D
    J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor.
    Soares MB; Titus RG; Shoemaker CB; David JR; Bozza M
    J Immunol; 1998 Feb; 160(4):1811-6. PubMed ID: 9469441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D; Delgado M
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
    Delgado M
    Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M; Reduta A; Sharma V; Ganea D
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
    Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
    Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
    Delgado M; Leceta J; Ganea D
    J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive Intestinal Peptide and pituary adenylate cyclase-activating polypeptide inhibit tissue factor expression in monocyte in vitro and in vivo.
    Lv B; Tang Y; Chen F; Xiao X
    Shock; 2009 Feb; 31(2):185-91. PubMed ID: 18650785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
    Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP
    J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Neuroimmunol; 1999 May; 96(2):167-81. PubMed ID: 10337915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.